We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

1 hedge funds and large institutions have $21.1K invested in Cymabay Therapeutics in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 198 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 200 → 1 (-199)

100% less funds holding in top 10

Funds holding in top 10: 10 → 0 (-10)

100% less capital invested

Capital invested by funds: $2.73B → $21.1K (-$2.73B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 198

Holders
1
Holders Change
-199
Holders Change %
-99.5%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-10
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
198
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$262M
2
BlackRock
BlackRock
New York
-$227M
3
RCM
RA Capital Management
Massachusetts
-$164M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$149M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$144M
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
51
Tang Capital Management
California
– -$8.27M -350,000 Closed
AllianceBernstein
52
AllianceBernstein
Tennessee
– -$8.26M -349,739 Closed
Citadel Advisors
53
Citadel Advisors
Florida
– -$7.8M -330,234 Closed
AG
54
Artal Group
Luxembourg
– -$7.17M -303,600 Closed
MAP
55
Moody Aldrich Partners
Massachusetts
– -$6.17M -261,415 Closed
Prudential Financial
56
Prudential Financial
New Jersey
– -$5.53M -233,921 Closed
SCM
57
Silverarc Capital Management
Massachusetts
– -$5.17M -218,975 Closed
EI
58
EAM Investors
California
– -$4.89M -207,152 Closed
Wellington Management Group
59
Wellington Management Group
Massachusetts
– -$4.79M -202,782 Closed
Jane Street
60
Jane Street
New York
– -$4.61M -194,968 Closed
Barclays
61
Barclays
United Kingdom
– -$4.5M -190,332 Closed
SC
62
Stempoint Capital
New York
– -$4.3M -182,258 Closed
ACH
63
ArrowMark Colorado Holdings
Colorado
– -$4.24M -179,400 Closed
ECM
64
ExodusPoint Capital Management
New York
– -$4.18M -177,072 Closed
BNP Paribas Financial Markets
65
BNP Paribas Financial Markets
France
– -$3.99M -169,082 Closed
JGC
66
J. Goldman & Co
New York
– -$3.92M -165,937 Closed
HS
67
HighVista Strategies
Massachusetts
– -$3.79M -160,334 Closed
Renaissance Technologies
68
Renaissance Technologies
New York
– -$3.78M -159,950 Closed
JP Morgan Chase
69
JP Morgan Chase
New York
– -$3.78M -159,857 Closed
TD Asset Management
70
TD Asset Management
Ontario, Canada
– -$3.72M -157,556 Closed
Swiss National Bank
71
Swiss National Bank
Switzerland
– -$3.67M -155,400 Closed
CS
72
Credit Suisse
Switzerland
– -$3.56M -150,752 Closed
RhumbLine Advisers
73
RhumbLine Advisers
Massachusetts
– -$3.55M -150,169 Closed
Two Sigma Investments
74
Two Sigma Investments
New York
– -$3.45M -146,189 Closed
ACM
75
Atika Capital Management
New York
– -$3.42M -145,000 Closed
1 2
3
4 5

CBAY Hedge Fund Activity: Q1 2024 in Review

1 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2024, worth a combined $21.1K — down 100% from $2.73B a quarter earlier.

Sellers outnumbered buyers: 198 funds closed out of CBAY and 0 opened new positions — a net loss of 198 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $262M sold.

  • 1 institutional investor held Cymabay Therapeutics (CBAY) as of Q1 2024, down from 200 in Q4 2023.
  • Funds reported $21.1K of Cymabay Therapeutics stock for Q1 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Cymabay Therapeutics positions in Q1 2024 and 198 closed out, a net change of -198 holders.
  • The largest Cymabay Therapeutics seller in Q1 2024 was Avoro Capital Advisors, an estimated $262M sold.

Based on aggregated 13F filings for Q1 2024.